Zeng Q - Search Results

1

CD137L dendritic cells induce potent response against cancer-associated viruses and polarize human CD8⁺ T cells to Tc1 phenotype.

Dharmadhikari B, Nickles E, Harfuddin Z, Ishak NDB, Zeng Q, Bertoletti A, Schwarz H. Dharmadhikari B, et al. Among authors: zeng q. Cancer Immunol Immunother. 2018 Jun;67(6):893-905. doi: 10.1007/s00262-018-2144-x. Epub 2018 Mar 5. Cancer Immunol Immunother. 2018. PMID: 29508025 Free PMC article.

2

Anti-CD137 Cancer Immunotherapy Suppresses Tumor Growth-Letter.

Dharmadhikari B, Zeng Q, Wu M, Schwarz H. Dharmadhikari B, et al. Among authors: zeng q. Cancer Res. 2018 Mar 15;78(6):1571. doi: 10.1158/0008-5472.CAN-17-2997. Epub 2018 Feb 28. Cancer Res. 2018. PMID: 29490949 No abstract available.

3

Increased Akt-Driven Glycolysis Is the Basis for the Higher Potency of CD137L-DCs.

Zeng Q, Mallilankaraman K, Schwarz H. Zeng Q, et al. Front Immunol. 2019 Apr 24;10:868. doi: 10.3389/fimmu.2019.00868. eCollection 2019. Front Immunol. 2019. PMID: 31068941 Free PMC article.

4

CD137L-DCs, Potent Immune-Stimulators-History, Characteristics, and Perspectives.

Zeng Q, Zhou Y, Schwarz H. Zeng Q, et al. Front Immunol. 2019 Oct 2;10:2216. doi: 10.3389/fimmu.2019.02216. eCollection 2019. Front Immunol. 2019. PMID: 31632390 Free PMC article. Review.

5

Epstein-Barr virus-induced ectopic CD137 expression helps nasopharyngeal carcinoma to escape immune surveillance and enables targeting by chimeric antigen receptors.

Prasad M, Ponnalagu S, Zeng Q, Luu K, Lang SM, Wong HY, Cheng MS, Wu M, Mallilankaraman K, Sobota RM, Lim YT, Wang LC, Goh CK, Tay KXJ, Loh KS, Wang CI, Lee WH, Goh BC, Lim CM, Schwarz H. Prasad M, et al. Among authors: zeng q. Cancer Immunol Immunother. 2022 Nov;71(11):2583-2596. doi: 10.1007/s00262-022-03183-8. Epub 2022 Mar 17. Cancer Immunol Immunother. 2022. PMID: 35299256 Free PMC article.

6

The role of trogocytosis in immune surveillance of Hodgkin lymphoma.

Zeng Q, Schwarz H. Zeng Q, et al. Oncoimmunology. 2020 Jun 17;9(1):1781334. doi: 10.1080/2162402X.2020.1781334. Oncoimmunology. 2020. PMID: 32934884 Free PMC article. Review.

7

CD137 ligand interacts with CD32a to trigger reverse CD137 ligand signaling.

Zeng Q, Soe YM, Lim Y, Sobota RM, Schwarz H. Zeng Q, et al. Cell Mol Immunol. 2020 Nov;17(11):1188-1189. doi: 10.1038/s41423-020-0370-6. Epub 2020 Feb 19. Cell Mol Immunol. 2020. PMID: 32076121 Free PMC article. No abstract available.

8

Regulatory T Cells Inhibit T Cell Activity by Downregulating CD137 Ligand via CD137 Trogocytosis.

Luu K, Patwardhan MV, Zeng Q, Wickström SL, Lundqvist A, Schwarz H. Luu K, et al. Among authors: zeng q. Cells. 2021 Feb 9;10(2):353. doi: 10.3390/cells10020353. Cells. 2021. PMID: 33572150 Free PMC article.

9

Ectopic CD137 expression by rhabdomyosarcoma provides selection advantages but allows immunotherapeutic targeting.

Lee KY, Wong HY, Zeng Q, Le Lin J, Cheng MS, Kuick CH, Chang KTE, Loh AHP, Schwarz H. Lee KY, et al. Among authors: zeng q. Oncoimmunology. 2021 Feb 4;10(1):1877459. doi: 10.1080/2162402X.2021.1877459. Oncoimmunology. 2021. PMID: 33643694 Free PMC article.

10

Plasma Factors for the Differentiation of Hodgkin's Lymphoma and Diffused Large B Cell Lymphoma and for Monitoring Remission.

Zeng Q, Gupta A, Xin L, Poon M, Schwarz H. Zeng Q, et al. J Hematol. 2019 Jun;8(2):47-54. doi: 10.14740/jh499. Epub 2019 Jun 30. J Hematol. 2019. PMID: 32300443 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7,836 results

Search Page

Filters